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Abstract
Cell culture technologies have provided biomedical researchers with fast and 
accessible tools to probe the breast tumor microenvironment. Exponential progress 
in fabrication methods combined with multiparametric approaches have enabled 
the development of cell culture model systems with enhanced biological complexity 
to identify key aspects that regulate breast cancer (BC) progression and therapeu-
tic response. Yet, the culture parameters and conditions employed influence the 
behavior of tumor cells, thereby affecting its tissue biomimetic capabilities. In this 
chapter we review the wide range of culture platforms employed for the generation 
of breast tumor models and summarize their biomimetic capabilities, advantages, 
disadvantages and specific applications.
Keywords: culture platforms, microfluidics, organoids, 3D bioprinting,  
tumor microenvironment, co-culture
1. Introduction
Cell culture is an integral tool in biomedical research. It refers to the removal of 
cells from tissues or organs, into an artificial in vitro environment. The cells may be 
directly removed from the tissue before culturing, or they may be derived from a 
previously established cell line [1, 2]. Among their many applications, in vitro cell 
culture models allow for the evaluation of the physiology and biochemistry of cells; 
the study of mutagenesis and carcinogenesis; and drug research and development 
[1–3]. Furthermore, in vitro models provide a faster and more cost-effective alterna-
tive to in vivo animal models, while also allowing researchers to control and alter the 
cellular microenvironment.
Breast tumors are complex systems, composed of different cell subpopulations 
with distinct tumorigenic capabilities within the tumor. In vitro cell culture models 
have been one of the basic techniques utilized in BC research. Despite the many 
advances in the field, there is still a need for suitable tumor models that can accu-
rately mimic the disease. Two-dimensional (2D) culture models have been com-
monly used in BC studies over the years. These have provided valuable insight about 
the molecular mechanisms involved in the pathology of the disease, yet 2D models 
are not able to properly model BC complexities [4]. Similarly, animal models require 
specialized animal facilities, are expensive, laborious, along with the consideration 
of pharmaco-and toxicokinetic differences between animal and humans which 
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can make results unreliable [5]. Hence, the development of tumor models that 
can mimic to some extent the complexity present in the tumor microenvironment 
(TME) is imperative.
The TME is heterogeneous and plays a significant role in tumor development, 
progression and metastasis [6]. It is composed of multiple cell types such as fibro-
blasts, myoepithelial and endothelial cells, infiltrated immune cells (e.g., T cells, 
macrophages), adipocytes and mesenchymal stem cells (MSC), along with the 
extracellular matrix (ECM) and soluble factors [7, 8]. These cell types are important 
for modeling the disease as it has been shown that tumor prognosis is not solely 
based on the tumorigenic cells, but also on how those cells communicate with their 
environment [9]. For example, cancer associated fibroblasts (CAFs) have been 
demonstrated to promote cancer cell aggressiveness and survival by the secretion of 
growth factors and cytokines and the creation of a “protective niche” against drugs 
[8, 10, 11]. Similarly, immune cells promote angiogenesis [12], immunosuppression, 
invasion and metastasis [13, 14]. Furthermore, adipocytes and MSCs have been 
shown to be involved in the secretion of factors related to matrix remodeling, inva-
sion and survival of the tumor [15, 16]. Thereby, models that include multiple cell 
types are likely to be more mimetic of the pathology and predictive of responses in 
tissues. As such, custom microscale platforms have been developed to accommodate 
multiple cell types in spatially defined patterns and locations to enable examination 
of multi-cell type interactions. Such models include those related to angiogenesis 
and metastatic processes [17–19], and due to the lack of spatial control it would have 
been difficult to recreate such interactions in traditional culture platforms high-
lighting the applicability of custom platforms for multi-cell type interactions.
The identification of relevant parameters from the tumor microenvironment 
is imperative for proper assessment and predictability of efficacy of experimental 
therapies. For this reason, 3D cell culture systems have become more popular due 
to its potential to better mimic the complexity of the TME and thereby increase the 
physiological relevance of the study [20, 21]. This modality incorporates scaffolds 
and 3D cell constructs that have been shown to impact cell proliferation, morphol-
ogy, signaling and drug resistance in a more physiologically relevant manner [22–25].
Mimicking BC complexity is challenging, however, progress in microfabrica-
tion techniques, tissue engineering and cancer biology have paved the way to more 
sophisticated models with enhanced biomimetic capabilities that will help to eluci-
date the intricate nature of BC. In this chapter, we discuss the wide range of culture 
platforms employed for the generation of breast tumor models and summarize their 
biomimetic capabilities, advantages, disadvantages and specific applications.
2. Cell culture modalities
2.1 Two-dimensional and three-dimensional culture
The traditional cell culture methods for studying breast cancer employ 
two-dimensional monolayer cultures, where cells grow flat on a surface. Two-
dimensional culture is still widely used, but with advances in microfabrication 
now surfaces can be modified with nanostructure topographies and different 
levels of stiffness to mimic to some extent the physical properties of the matrix 
surface. These topographies (e.g., roughness, surface geometry) have the capa-
bility of providing biomimetic surfaces that have been shown to modify the 
morphology, proliferation and signaling, among others, of cells [26]. Similarly, 
changes in the mechanical properties of the ECM (e.g., stiffness) are related to 
increasing malignant phenotype [27], cancer progression, signaling [28–30] and 
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drug sensitivity [31]. Despite these technological advances in 2D cultures, multiple 
studies have shown that cell cultures in 2D felt short to mimic cell phenotypes 
associated with disease progress such as cell invasion, cell function and expression 
of pathological markers [4, 23, 32]. In some cases, utilizing 2D culture systems has 
resulted in the loss of essential cell signaling pathways, hence limiting the ability 
to fully evaluate cell–cell and cell-ECM interactions [33]. Evidence has also shown 
that there are inconsistencies when comparing cell morphology, receptor expres-
sion, and polarity between cells grown in 2D and the in vivo setting [34].
In order to bridge this gap in biological complexity, multiple methods employing 
3D cell culture systems have emerged and continue to be steadily improving, aiming 
to produce the most in vivo-like structures. Essentially, 3D models can be divided 
into two groups: cell aggregates (spheroids) and biomaterial constructs [35]. The 
most basic 3D culture models use scaffolds of synthetic (e.g., polydimethylsiloxane-
PDMS, polylactic acid-PLA) and natural (e.g., collagen, Matrigel®, hydrogels) bio-
materials to investigate the effect of ECM properties on cancer behavior. Spheroids 
have been used mostly for drug screening applications since it has been demon-
strated they more closely resemble the in vivo environment [36]. Growing BC cells 
in 3D has also revealed a more realistic drug response [21, 37], cell proliferation and 
morphology [38], and better representation of tumor heterotypic phenotype and 
TME [39, 40]. For example, single-cell RNA sequencing of breast cancer spheroids 
have uncovered cell clusters with specific functions (e.g., proliferation, invasion) 
that provide evidence of the heterotypic nature and complexity of breast tumors 
[41]. Figure 1 below depicts the main in vitro 2D and 3D culture modalities along 
with the most predominant co-culture models (discussed in the next subsection) to 
study cell crosstalk.
2.2 Co-culture
Cancer is a heterogeneous disease and even though there have been various 
advances in cell culture modalities, thorough comprehension of the crosstalk 
between cancer and non-cancer cells is still not fully understood [42]. Co-culture 
and multi-culture models have been long established as appropriate tools for 
Figure 1. 
In vitro culture modalities. A) Cells can be cultured in vitro as 2D monolayers, over a 3D scaffold (synthetic 
or natural material), embedded into a scaffold material or as spheroid constructs. B) Yet, co-culture and 
multi-culture models are implemented in order to better understand tumor-stroma interactions and cross-talk. 
The three main co-culture modalities used are compartmentalized, conditioned media and mixed, which 
incorporate cells cultured in 2D monolayers, 3D scaffolds or spheroids. Created with BioRender.com
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evaluating breast cancer heterotypic interactions in vitro [6]. Co-culture refers to 
the culturing of two different cell lines, while multi-culture models involve three 
or more different cells. Historically, co-culture models have been the predominant 
approach in research. However, despite their ability to identify factors mediating 
cancer and stromal interactions, co-culture models are deficient in incorporating 
microenvironment structure, dimensionality, and functional response [42]. With 
the hopes of bridging the gap between in vitro and in vivo studies, new research 
has been moving away from the study of only two cell types, to studying multi-cell 
type systems. This type of model permits researchers to control and evaluate the 
influence of each cell culture component. It also allows the study of important 
cell–cell heterotypic signals, which would be impossible to study with a 2-cell type 
model [43].
There have been an increasing number of studies looking to compare tri-culture 
models with the more traditional mono-culture or co-culture methods. With 
the intention of better understanding the bone microenvironment, Pagani et al. 
compared a tri-culture model of osteoblasts, osteoclasts, and endothelial cells; to 
single and co-cultures. The results demonstrated that the behavior of the three cell 
types cultured together was very different from the single or the co-culture model, 
in terms of proliferation, activity, and viability. These results correlate with previ-
ously established data regarding their behavior in vivo [44]. Regier et al. evaluated 
how increased model complexity would affect gene expression. The results demon-
strated that gene expression changes based on the type of model utilized; suggest-
ing how tumor and stromal cells would respond to microenvironments of increased 
complexity in vivo [42]. Loy et al. investigated the effect a tri-culture model would 
have on angiogenesis and compared it to simpler models. The results showed that 
the tri-culture model promoted cell-matrix remodeling and early expression of 
elastic fiber-related proteins. It also reiterated the significance of multi-culture 
methods since culturing with fibroblasts, endothelial cells, and smooth muscle cells 
was required to obtain tissues with appropriate physiological-like properties [45]. 
All three of these studies highlight the increasing need and importance of more 
complex heterotypic cultures.
Co-culture models involve a cell growing arrangement, where two or more 
different cells are cultured with some amount of contact between them [46]. The 
communication between the cells may be bi-directional or multi-dimensional, and 
it can happen at the macro-scale or at the micro-scale [47]. The method of choice 
should be dependent on what is the focus of each individual study and can be 
grouped in: compartmentalized, conditioned media and mixed culture.
2.2.1 Compartmentalized
The segregated or compartmentalized model consists of two or more physi-
cally separated cells, cultured in a shared environment [6]. This type of culture 
is preferred when studying paracrine interactions of cells that are not located in 
close proximity in tissues. Also, this method is useful to identify target cells based 
on soluble factor signaling since the cells individual response can be examined, 
facilitating the identification of factors that may play a role in tumor growth and 
advancement. In compartmentalized co-cultures, one cell population is seeded 
in the bottom of the standard well, and the other is seeded on a top insert or in an 
adjacent compartment. By doing this, the cell types remain separated, while still 
being able to exchange soluble signals in their shared environment [48]. Indirect 
cell culture eliminates heterotypic interactions mediated by contact between the 
cell types, which can be seen in direct cell culture. It also allows for cell type spe-
cific readouts, which are unachievable in direct cell culture [6]. Such method has 
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provided evidence on genes involved behind stromal invasiveness and metastasis, 
and the crucial role of fibroblasts in proliferation of estrogen-dependent human 
breast carcinomas [6, 49, 50]. Gonzalez et al. utilized a 2D indirect co-culture 
method with human BC cells and human umbilical vein endothelial cells to evaluate 
the process behind angiogenesis; concluding that melatonin may be an alternative 
for preventing tumor angiogenesis [51]. While Chiovaro et al. analyzed the role of 
ECM proteins in bone metastasis, showing that tenascin-W promotes cancer cell 
migration and proliferation [52].
If multiple cells need to be examined, co-culture platforms, such as transwells, 
are not useful since they are limited to only two compartments. Hence, the use of 
customizable culture systems such as microscale devices, is warranted [6]. Our 
group developed compartmentalized microwell culture platforms, in which we 
show the contribution of multiple cell types to the sensitivity to heat therapy in 
tumor cells [43]. The data shown indicates that the presence of macrophages and 
fibroblasts had a significant protective effect against heat stress in BC cells, thus, 
perturbing the effectiveness of heat therapy. Others have employed multi-cell type 
cultures to deconvolute cell communication of metastatic breast tumors. Regier 
et al. developed a compartmentalized multi-culture method, utilizing BC epithelial 
cells, bone marrow cells, and human monocytes. The platform allowed the creation 
of a substantial dataset made up of cell specific gene expression patterns. This 
was possible by collecting data from an individual cell type, while communicating 
through paracrine interactions in a heterotypic culture. The study also compared 
tri-culture to mono-culture and co-culture, which led to the demonstration of how 
stromal and tumor cells respond differently based on the complexity of the micro-
environment [42]. This reiterates the importance of utilizing multi-cultures versus 
the more traditional co-cultures. A drawback with this method is that physical 
contact between cells cannot be completely prevented in the long term [47]. In addi-
tion, because cell-seeding sometimes requires more than one step, the process may 
be considered somewhat complicated and time-consuming [6].
2.2.2 Conditioned media
Conditioned media transfer utilizes two separately cultured cell populations, 
where one culture medium is utilized to nourish the other [48]. This type of method 
is simple and allows one-way signaling from effector to responder [6]. The advan-
tage of utilizing this method is that conditioned media can be profiled for the iden-
tification of secreted soluble factor-related effects is possible [47]. Consequently, 
the role of signaling molecules could be tested in a specific response [6]. Also, this 
method is useful when the cells of interest cannot be cultured together such as stud-
ies involving tumor cells and microbes [53]. However, when employing multiple cell 
types, the method becomes a bit more complex since identification of the secretor 
and recipient cells can be complicated. Additionally, when this type of method is 
utilized, there is no cross-communication within the cells and it is not possible to 
study bi-directional signals [48]. For this reason, this type of method would not be 
ideal if the goal is to study multi-cell type interactions that naturally occur in the in 
vivo tumor environment.
2.2.3 Mixed co-culture
In mixed cell culture, different types of cells are cultured together. Just as with 
conditioned media transfer, this type of method is accessible and simple. It can be 
done in 2D or 3D using traditional well plates [6]. If the cells are cultured together 
in a standard plate, the method is referred to as direct or mixed cell culture. 
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However, if a transwell insert or adjacent compartments are utilized, the method 
is denoted as indirect or compartmentalized cell culture. Unlike the conditioned 
media method, mixed co-culture does allow for bi-directional paracrine and 
juxtacrine signaling, which is of great importance when studying multi-cell type 
interactions in breast cancer [6]. Because of the cellular arrangement, this method 
is also ideal for studying how cell–cell contact affects cell behavior [54]. When 
performing multi-cell type studies, the direct method simply requires the inclusion 
of the additional cell lines mixed.
Mixed co-culture experiments shed light on distinct microenvironment features 
based on cancer subtype; and potential mechanisms behind invasive phenotypes 
[55, 56]. Camp et al. compared the interaction of fibroblasts with the basal-like 
subtype versus the luminal subtype. The results were increased migration and 
expression of interleukins in the basal-like BC cell lines, which reiterates the 
important role of the TME in cancer progression [10]. Buess et al. also looked into 
evaluating the role of aspects of the TME by studying tumor-endothelial interac-
tions and determining gene expression changes [56]. Multiple other studies have 
been done utilizing these culture modalities and have provided insight into further 
understanding the disease [6]. Yet, a disadvantage of this method is the lack of 
control of the spatial location of cells which can be important when examining 
and quantifying changes in some tumor cell behaviors such as cell migration and 
invasion. Also, single cell studies will require multiple cell separation steps that will 
make this method more time consuming and increase the number of cells needed 
for analysis due to cell loss during sample handling.
3. Culture platforms for enhanced biomimetic capabilities
Despite the development and application of the aforementioned cell culture 
methods, thorough understanding of cancer development and progression contin-
ues to be a challenge. As shown in Figure 2, in vitro cell models are mainly cat-
egorized in 2D and 3D (as discussed before) and thus, these models become more 
complex as research continues to be centered on creating experimental models that 
can mimic cell evolution on the bench with the goal of understanding the biology of 
the disease and identifying key therapeutic targets. Despite the advances that came 
with the implementation of 3D multi-culture systems, there still remains a scarcity 
of models that can recreate the biological complexity of the tumor microenviron-
ment. Biomimetics can be defined as technology that utilizes or emulates tissue 
function with the intention of improving human lives [57]. Effective biomimetic 
models need to contribute a 3D environment permissive of cell phenotypic stages 
while enabling multi-cell type interactions [58]. As cell culture methods continue 
to evolve, innovative approaches are being created with the hopes of overcoming 
the limitations of the more traditional methods. Table 1 summarizes the advan-
tages, disadvantages and applications of advanced biomimetic in vitro 3D culture 
technologies.
3.1 Microfluidics
Microfluidic platforms can be utilized to scale down the traditional culture 
modalities, yet they enable to customize the culture environments to examine more 
complex interactions [64]. This technology employs microsystems that allow the 
manipulation of small fluid volumes and control over the spatial location of cell 
clusters [70]. Its application to improve 3D cell culture models has been increasing 
since 2012, particularly in BC research [71]. In comparison to macroscopic culture, 
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microfluidic cell culture models have several significant advantages that, when 
employed, lead towards better biomimetic models. Firstly, cells may be cultured 
in a spatially controlled environment by controlling fluid patterns and proximity 
across culture compartments [72–77]. This technology permits the combination 
of multiple cell types and to control cell patterning, to recapitulate to some extent 
tissue observations. For example, microfluidic devices permit the study of angio-
genesis while also allowing the study of endothelial migration and evaluation of 
cell response in co-culture [71, 78]. Also, microfluidics can implement continuous 
perfusion conditions, and controlled gradients, which are both characteristics that 
also resemble the cancerous in vivo environment more closely. Gradients are found 
in angiogenesis, invasion, and migration whereas perfusion is crucial in vasculature 
and cell extravasation as well for nutrient replenishment. Finally, microfluidic sys-
tems enable high-throughput arrays and pose lower contamination risk and reagent 
consumption which make them very appealing for studies with limited cell samples 
such as those that employ patient-derived tissues [70, 71].
Recent studies in microfluidic systems have highlighted their capability to 
recreate and profile some of the biological complexity of the tumor microenviron-
ment. Such studies have revealed important information regarding the processes 
involved in metastasis and how the tumor microenvironment contributes. For 
example, single cell RNA sequencing using microfluidic devices have revealed the 
diversity of the breast epithelium, which sheds light about early tumorigenesis and 
tumor progression [79, 80]. In addition, microfluidic devices pose as an advantage 
Figure 2. 
Culture platforms employed in breast cancer models. A) Simple 2D platforms consist of cells cultured in flat, 
nano- or micro- structured substrates (left) that mimic to some extent tissue topography; or they can combine 
co-culture and microfluidic devices (right) to increase the complexity of the model and better resemble 
tumor-stroma interactions. B) In three-dimensional models, cells are culture in scaffolds and constructs that 
further imitate the architecture of the tumor (left). Co-culture and advanced 3D models such as microfluidics, 
bioprinting and organoids are capable of duplicating the TME and provide physiologically relevant insights 
about the disease (right). Created with BioRender.com
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to personalized medicine by aiding in the selection of appropriate pharma-
cologic agents. In this regard, Lanz et al. developed a 3D microfluidic device, 
OrganoPlate®, to be utilized for therapy selection. They showed that MDA-MB-231 
(cell line isolated at MD Anderson from a pleural effusion of a 51-year old 
Caucasian woman) cells embedded in Matrigel® became more sensitive to the drug, 
thus confirming along with previous studies that drug response is tuned by the 
ECM. The results were promising and even though further validation is warranted, 
it appears to be a fine tool for pharmacologic selection and response prediction [37]. 
Similarly, Yildiz-Ozturk et al. studied the cytotoxicity of carnosic acid and doxoru-
bicin on MCF-7 and MDA-MB-231 BC cell lines and demonstrated the importance 
of biomimicry in in vitro platforms [20]. A breast metastatic microfluidic model was 
developed by Kong et al. to mimic the metastasis of circulating breast cancer cells 
(CBCCs) to the lung and other organs. Their microfluidic device allowed the flow 
of CBCCs over primary cell culture chambers, which would have been impossible 
with static conditions. They demonstrated that the metastatic potential of these cell 
lines was in concordance with animal models, providing a cost-effective and time-
saving alternative [81]. Bersini et al. also developed a microfluidic co-culture model 
made up of metastatic BC cells, and collagen gel-embedded bone marrow-derived 
stem cells (hBM-MSC) lined with endothelial cells to create an osteo-conditioned 
microenvironment and access extravasation and micrometastases to bone tissue 
[59]. They found that BC receptors CXCR2 and bone-secreted chemokine CXCL5 
play major roles in the extravasation process. However, due to the complexity of the 
design, their platform is not high throughput compatible, which adds many chal-
lenges, particularly to obtain multiple replicates in a short time. Also, in general it 
is important to notice that most of the organ on chip microfluidic platforms focus 
on the metastatic stage of the disease, leaving an evident need for research focusing 
Model Advantages Disadvantages Application Ref.
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on the early stages of breast cancer. Yet, some efforts are being done to overcome 
this gap. As an example, Choi et al. developed a compartmentalized microfluidic 
device that enabled co-culture of tumor spheroids and normal mammary epithelial 
cells in close proximity to fibroblasts, with the goal of providing a model that allows 
researchers to closely examine the mechanistic progression of early-stage breast 
ductal carcinoma in situ (DCIS) [82].
Even though microfluidic devices have given the opportunity to better repli-
cate the tumor environment, there are still some caveats to its use. Silicone-based 
devices have been shown to sequester small hydrophobic molecules, which can 
compromise the results of some studies [70], yet researchers have been addressing 
this by modifying the material to make it more hydrophilic and reduce molecule 
sequestration [60]. Also, microfluidic devices in some cases can induce mechani-
cal stress to the cells [83], which can modulate cell responses in an unpredictable 
manner, and are often limited by complicated set-ups [70], which limits their broad 
adoption by the scientific and clinical community. As such, simpler fabrication 
methods and commercial availability of customizable microscale platforms is desir-
able to overcome such limitations.
3.2 Bioreactors
Despite the numerous advantages of the aforementioned 3D culture methods, 
the duration of culture and nutrient availability can be a limitation in static cultures 
particularly to enable observations that occur in cells over periods of several weeks. 
In this case, perfusive systems, such as bioreactors, are more appropriate. A biore-
actor is a canister that allows the 3D culture of cell clusters for extended periods of 
time. It is coupled to sensors and actuator components allowing for the controlled 
delivery of oxygen, nutrients and other parameters [84]. Goliwas et al. developed 
a perfused 3D BC surrogate model utilizing a bioreactor system that incorporated 
breast carcinoma epithelial cells and stromal fibroblasts into an extracellular 
matrix. The study demonstrated that using a bioreactor allowed for analysis of 
longer growth periods and a greater degree of growth when compared to solid 
models [85]. Bioreactors have also been utilized to study metastatic progression of 
breast cancer, and as potential drug development platforms for cancer treatment. 
Krishnan et al. utilized a compartmentalized bioreactor model, with osteoblasts 
and metastatic BC cells, to study the colonization of osteoblastic tissue. In their 
design, cultured osteoblasts were monitored over longer periods and exhibited 
more in vivo-like characteristics, compared to 2D cell cultures [86]. Marshall et al. 
developed a physiologically relevant bioreactor system that could be potentially 
used for pharmacologic development. Their construct was capable of supporting 
and perfusing larger volume, which poses as an advantage to lab-on-a-chip systems 
[62]. Other studies have also used bioreactors to assess drug response of BC tis-
sue [63, 87]. Despite bioreactors being an ideal option for cultures that require 
long-term analysis, there are some factors that might damper their use. Membrane 
bioreactors may become contaminated and multilayer cell growth may cause 
transfer limitations [88]. Also, its complex composition and dimensionality limits 
their implementation in convectional labs and limits the number of experimental 
replicates [89].
3.3 Three-dimensional (3D) bioprinting
Another technology that has emerged in recent years and that is being applied 
to 3D culture technology is 3D bioprinting. Its development has been possible 
thanks to advances in 3D printing technology, biomaterials and tissue engineering 
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methods. Three-dimensional (3D) bioprinting consists of printing cells together 
with ECM components, biomaterials and bioactive factors [90]. It has been shown 
that bioprinting techniques can be used to generate 3D tumor models that can 
better resemble the TME [90, 91]. This has been achieved as bioprinting provides 
the ability of controlling the spatial arrangement of cells, creating biomolecular 
gradients and well-organized vessel-like structures (vasculature) within a micron 
scale resolution [92, 93]. Therefore, bioprinted tumor models are used for angio-
genesis, migration and drug development and screening studies as well as TME 
models [65, 94]. Although 3D bioprinting is widely used in tumor research, very 
few studies use bioprinted models for BC. Yet, most of these studies are focused on 
BC metastasis and drug resistance. A study performed by Zhou et al. evaluated the 
interaction between triple negative breast cancer cells (TNBC) and osteoblasts to 
assess metastatic progression in bone. They found that osteoblasts increased VEGF 
secretion and therefore, enhanced the proliferation of BC cells, while osteoblast 
proliferation was inhibited [58]. Bioprinted BC models have also been used for 
drug resistance studies. Swaminathan et al. bioprinted pre-formed MDA-MB-231 
spheroids along with breast epithelial cells and vascular endothelial cells and evalu-
ated plaxitacel chemoresistance in mono and co-culture. They demonstrated that 
bioprinted spheroids are more resistant to plaxitacel as it has been shown before in 
other studies. Yet, this resistance was decreased in co-culture with vascular endo-
thelial cells highlighting the importance of replicating the TME complexities in vitro 
[95]. Another study by Duan et al. examined drug resistance using 3D bioprinted 
constructs of BC cells and adipose-derived mesenchymal stem cells (ADMSC). 
They found increased chemoresistance in BC cells cultured with ADMSC in com-
parison to monoculture and, thus provided a model to better understand the role of 
ADMSC in BC progression [66]. Likewise, Campbell et al. bioprinted MCF-7 cancer 
cells and showed higher resistance to Tamoxifen compared to monolayer culture, 
providing a more biological-like behavior [66, 96]. Despite the flexibility of 3D 
bioprinting systems, there are some challenges that need to be overcome to ease its 
application. Maintaining high viability and original phenotype is an issue in some 
bioprinting techniques due to exposure of cells to shear stress. Therefore, close 
control of bioink viscosities, extrusion rates, among other parameters, is imperative 
[97]. Also, lack of process standardization and guidelines pose another challenge for 
study comparison and reproducibility.
3.4 Organoids
The most recent 3D cell culture modality are organoids. These are 3D heterotypic 
in vitro tissue constructs, derived either from primary tissue or stem cells, that have 
the ability to mimic the in vivo organ [98, 99]. Historically, established cancer cell 
lines have been widely utilized as single cell models of the cancer disease. However, 
their use has several drawbacks in terms of their capability to mimic the pathology 
of the patient. Cell lines can undergo genetic changes, losing the genetic heterogene-
ity of the original tumor [100]. Organoids also possess substantial similarities to 
cancer cell lines 3D models (spheroids) such as cell–cell and cell-matrix interactions, 
gradients of nutrients, oxygen and metabolites, and can be replaced from frozen 
supplies with ease. They are also relatively easy to handle and can be grown in infi-
nite quantities [101]. Yet, the main characteristic of organoids is their capability to 
closely resemble and retain the pathology of the parental tumor over several rounds 
of expansion in vitro [102, 103]. They also have shown therapeutic predictability 
for some drugs and can be preserved as biobanks and expanded, which allows 
extended incubation [98, 99]. Given the number of mutational processes involved 
in cancer development and progression, being able to study tumorigenesis in depth 
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is crucial. Organoids allow for organ-specific mutations to be analyzed and their 
whole genomes to be sequenced. Intratumor heterogeneity can also be analyzed by 
growing organoids from separate sections of the same tumor [100]. Another area 
where organoids can play a major role is drug development. Organoids appear to 
be much better models for identifying and testing anticancer drugs yet in a patient 
specific manner. For instance, studies on single cell transcriptomics of organoids 
have detected differences in drug sensitivity, proving that organoids maintain tumor 
heterogeneity, which is considered a critical aspect of tumor models [104].
Studies with BC organoids are limited, since this modality has just started to be 
explored. However, they have gained more popularity in the last few years. Cheung 
et al. used breast carcinoma organoids to understand tumor invasiveness and 
metastasis. They found that the heterotypic interactions between epithelial sub-
groups are key to collective invasion [105]. Broutier et al. was able to demonstrate 
that liver cancer derived organoids could be utilized for drug screening testing and 
identification of potential pharmacologic targets [68]. Sachs et al. demonstrated 
the biomimetic nature of organoids by demonstrating the reflecting histopathology 
of in vivo tumors, as well as HER2 and hormone receptor status. Moreover, drug 
screening tests were consistent with patient response [69]. These promising find-
ings suggest that organoids will be an ideal alternative model for cancer research. 
Nonetheless, successfully cultivating patient organoids from biopsy specimens 
is still a challenge mainly due to low cell recovery and heterogeneity of collected 
samples, and limited availability of standardized methods [103, 105].
4. Concluding remarks
Breast cancer is an evolutionary disease and cell culture modalities should con-
tinue to evolve concomitantly. Even though traditional 2D co-culture methods have 
provided valuable insights on disease development and progression, there is a need 
for more heterotypic biomimetic models that can replicate the tumor environment 
more closely. Some of the consequences of limited biomimetic models has been the 
large number of investigational drugs that never make it past clinical trials and the 
lack of clear understanding on the foundations of breast cancer malignant trans-
formation. Aside from the need for more biomimetic models, most of the current 
research has been focused on the metastatic stage of the disease. Even though under-
standing tumor progression and the role of its microenvironment is of utmost impor-
tance, understanding the early and localized stages of breast cancer is also imperative. 
Not having an explicit grasp on the biological processes behind progression from 
early stage to invasive to metastasis has hindered the ability to make a predictive 
diagnosis in patients with early disease that have a greater probability of invasive 
cancer progression. Hence, designing new targeted pharmacologic agents becomes a 
challenge. Despite the continuous development of innovative cell culture modalities, 
there are still many unanswered questions. However, the hope is that with the emer-
gence of the new methods (bioreactors, organoids, etc.), many of these questions can 
be interrogated in a controlled and user friendly cell culture environment.
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